---
title: "KHB (002022): Won the procurement project of Tangshan Central Blood Station, with a bid amount of 1.1827 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287017122.md"
description: "KHB (002022) won the bid for the procurement project of Tangshan Central Blood Station, with an amount of 1.1827 million yuan. The operating revenue for 2024 is 1.759 billion yuan, with a net profit of -641 million yuan and a return on net assets of -17.02%. In the first half of 2025, the operating revenue is 794 million yuan, with a net profit of -133 million yuan. The company's main products include genetic products and biological diagnostic reagents"
datetime: "2026-05-20T06:36:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287017122.md)
  - [en](https://longbridge.com/en/news/287017122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287017122.md)
generator: "portal-rs"
---

# KHB (002022): Won the procurement project of Tangshan Central Blood Station, with a bid amount of 1.1827 million yuan

According to Tongbi Finance, data from Qichacha shows that based on the announcement of the results of the "Z1302002600242021 Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus (Type 1+2) Nucleic Acid Testing Reagents (PCR-Fluorescence Method) (Double-Blind Review)", Shanghai KHB Biotechnology Co., Ltd. announced on May 20, 2026, that it won the bid for the procurement project of the Tangshan Central Blood Station, with a bid amount of 1.1827 million yuan.

Related listed company: KHB (002022.SZ)

*Tongbi Finance Tip:*

*KHB (002022.SZ) reported an operating income of 1.759 billion yuan in 2024, with an operating income growth rate of -27.55%. The net profit attributable to the parent company was -641 million yuan, with a net profit growth rate of -173.74%, and a return on net assets of -17.02%.*

*In the first half of 2025, the company's operating income was 794 million yuan, with an operating income growth rate of -12.65%. The net profit attributable to the parent company was -133 million yuan, with a net profit growth rate of -154.37%.*

*The company currently belongs to the healthcare industry, with main product types including genetic products, biological diagnostic reagents, system integration services, industry-specific software, and diagnostic treatment equipment. The 2024 report shows that the main composition of its business is self-produced products: 49.22%; agency products: 47.63%; others: 3.15%.*

### Related Stocks

- [002022.CN](https://longbridge.com/en/quote/002022.CN.md)

## Related News & Research

- [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md)
- [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)
- [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**